Prognostic significance of immunohistochemical markers in adrenocortical carcinoma

References

• Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130–3136.
   PubMed Web of Science ®Google Scholar
• Kerkhofs TM, Verhoeven RH, Bonjer HJ, et al. Dutch Adrenal Network Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data. Eur J Endocrinol. 2013;16:83–89.
   Web of Science ®Google Scholar
• O'Neill CJ, Spence A, Logan B, et al. Adrenal incidentalomas: risk of adrenocortical carcinoma and clinical outcomes. J Surg Oncol. 2010;102:450–453.
   PubMed Web of Science ®Google Scholar
• Keskin S, Tas F, Vatansever S. Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome. Urol Int. 2013;90:435–438.
   PubMed Web of Science ®Google Scholar
• Dong D, Li H, Yan W, et al. Surgical management and clinical prognosis of adrenocortical carcinoma. Urol Int. 2012;88:400–404.
   PubMed Web of Science ®Google Scholar
• Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253 patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25:891–897.
   PubMed Web of Science ®Google Scholar
• Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13:202–206.
   PubMed Web of Science ®Google Scholar
• Aiba M, Fujibayashi M. Histopathological diagnosis and prognostic factors in adrenocortical carcinoma. Endocr Pathol 2005;16:13–22.
   PubMed Web of Science ®Google Scholar
• MacFarlane DA. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl. 1958;23:155–186.
   PubMedGoogle Scholar
• Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol. 1978;120:660–665.
   PubMed Web of Science ®Google Scholar
• Hofland J, Feelders RA, van der Wal R, et al. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas. Eur J Endocrinol. 2012;166:281–289.
   PubMed Web of Science ®Google Scholar
• Wang C, Sun Y, Wu H, et al. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers. Histopathology. 2014;64:567–576.
   PubMed Web of Science ®Google Scholar
• Giordano TJ. Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas. Endocr Pathol. 2006;17:355–363.
   PubMed Web of Science ®Google Scholar
• Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009;40:757–768.
   PubMed Web of Science ®Google Scholar
• Soon PS, Gill AJ, Benn DE, et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer. 2009;16:573–583.
   PubMed Web of Science ®Google Scholar
• Sasano H, Suzuki T, Moriya T. Discerning malignancy in resected adrenocortical neoplasms. Ep. 2001;12:397–406.
   Web of Science ®Google Scholar
• Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J. 2008;55:49–55.
   PubMed Web of Science ®Google Scholar
• Stojadinovic A, Brennan MF, Hoos A, et al. Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. Mod Pathol. 2003;16:742–751.
   PubMed Web of Science ®Google Scholar
• McNicol AM, Struthers AL, Nolan CE, et al. Proliferation in adrenocortical tumors: correlation with clinical outcome and p53 status. Endocr Pathol. 1997;8:29–36.
   PubMed Web of Science ®Google Scholar
• Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. Jco. 2002;20:941–950.
   PubMed Web of Science ®Google Scholar
• Advani A, Vaikkakara S, Gill MS, et al. Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review. J Clin Pathol. 2008;61:939–944.
   PubMed Web of Science ®Google Scholar
• Iino K, Sasano H, Yabuki N, et al. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol. 1997;10:901–907.
   PubMed Web of Science ®Google Scholar
• Nakazumi H, Sasano H, Iino K, et al. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod Pathol. 1998;11:1165–1170.
   PubMed Web of Science ®Google Scholar
• Mondal SK, Dasgupta S, Jain P, et al. Histopathological study of adrenocortical carcinoma with special reference to the Weiss system and TNM staging and the role of immunohistochemistry to differentiate it from renal cell carcinoma. J Can Res Ther. 2013;9:436–441.
   PubMed Web of Science ®Google Scholar
• Weissferdt A, Phan A, Suster S, et al. Myxoid adrenocortical carcinoma: a clinicopathologic and immunohistochemical study of 7 cases, including 1 case with lipomatous metaplasia. Am J Clin Pathol. 2013;139:780–786.
   PubMed Web of Science ®Google Scholar
• Weissferdt A, Phan A, Suster S, et al. Adrenocortical carcinoma: a comprehensive immunohistochemical study of 40 cases. Appl Immunohistochem Mol Morphol. 2014;22:24–30.
   PubMedGoogle Scholar
• Gaffey MJ, Traweek ST, Mills SE, et al. Cytokeratin expression in adrenocortical neoplasia: an immunohistochemical and biochemical study with implications for the differential diagnosis of adrenocortical, hepatocellular, and renal cell carcinoma. Hum Pathol. 1992;23:144–153.
   PubMed Web of Science ®Google Scholar
• Pan CC, Chen PC, Tsay SH, et al. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol. 2005;13:347–352.
   PubMedGoogle Scholar
• Browning L, Bailey D, Parker A. D2-40 is a sensitive and specific marker in differentiating primary adrenal cortical tumours from both metastatic clear cell renal cell carcinoma and phaeochromocytoma. J Clin Pathol. 2007;61:293–296.
   PubMed Web of Science ®Google Scholar
• Ghorab Z, Jorda M, Ganjei P, et al. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Appl Immunohistochem Mol Morphol. 2003;11:330–333.
   PubMedGoogle Scholar